Mesoblast
(ASX:MSB) today reported its operational highlights for their fourth quarter showing growth in revenues achieved by their Japanese partner in the treatment of acute graft versus host disease in the first three years post launch.
They saw increased revenues of 54 per cent for the quarter and 37 per cent for the year on sales of TEMCELL® in Japan by Mesoblast licensee JCR Pharmaceuticals.
Mesoblast initiated a rolling Biologics License Application (BLA) with the United States Food and Drug Administration (FDA) for remestemcel-L in the treatment of pediatric aGVHD.
Mesoblast
(ASX:MSB) is a world leader in developing allogeneic, off-the-shelf, cellular medicines.
Shares in Mesoblast
(ASX:MSB) are currently trading at trading 1.4 per cent higher at $1.49
